Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 2
1914 2
1918 1
1920 1
1921 1
1924 1
1945 2
1947 3
1949 2
1950 1
1953 1
1955 1
1957 1
1959 1
1960 2
1961 2
1962 1
1965 1
1966 1
1967 1
1968 1
1970 3
1971 1
1973 1
1974 3
1975 8
1976 6
1977 3
1978 1
1979 8
1980 2
1981 6
1982 11
1983 6
1984 6
1985 6
1986 6
1987 6
1988 11
1989 10
1990 7
1991 6
1992 9
1993 16
1994 8
1995 10
1996 13
1997 19
1998 29
1999 19
2000 24
2001 24
2002 34
2003 17
2004 22
2005 15
2006 28
2007 29
2008 19
2009 21
2010 24
2011 18
2012 23
2013 42
2014 52
2015 64
2016 71
2017 56
2018 63
2019 66
2020 86
2021 95
2022 78
2023 65
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,212 results

Results by year

Filters applied: . Clear all
Page 1
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, Foster D, Huang SA, Rhyee S, Sweetser MT, Bakris GL. Desai AS, et al. Among authors: webb dj. N Engl J Med. 2023 Jul 20;389(3):228-238. doi: 10.1056/NEJMoa2208391. N Engl J Med. 2023. PMID: 37467498 Clinical Trial.
In Part A, patients receiving zilebesiran had decreases in serum angiotensinogen levels that were correlated with the administered dose (r = -0.56 at week 8; 95% confidence interval, -0.69 to -0.39). ...
In Part A, patients receiving zilebesiran had decreases in serum angiotensinogen levels that were correlated with the administered dose ( …
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years.
Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, Kodali SK, Kapadia SR, Cohen DJ, Pocock SJ, Lu M, White R, Szerlip M, Ternacle J, Malaisrie SC, Herrmann HC, Szeto WY, Russo MJ, Babaliaros V, Smith CR, Blanke P, Webb JG, Makkar R; PARTNER 3 Investigators. Mack MJ, et al. Among authors: webb jg. N Engl J Med. 2023 Nov 23;389(21):1949-1960. doi: 10.1056/NEJMoa2307447. Epub 2023 Oct 24. N Engl J Med. 2023. PMID: 37874020 Clinical Trial.
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Kumar S, et al. Among authors: webb ij. Blood. 2012 May 10;119(19):4375-82. doi: 10.1182/blood-2011-11-395749. Epub 2012 Mar 15. Blood. 2012. PMID: 22422823 Free article. Clinical Trial.
Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized phase 2 trial evaluated VDC, VDR, and VDCR in previously untreated multiple myeloma (MM). Patients received V 1.3 mg/m …
Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant effi …
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D. Fields PA, et al. Among authors: webb a. J Clin Oncol. 2014 Feb 1;32(4):282-7. doi: 10.1200/JCO.2013.49.7586. Epub 2013 Nov 12. J Clin Oncol. 2014. PMID: 24220559 Clinical Trial.
We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy because of cardiac comorbidity. PATIENTS AND METHODS: Sixty- …
We designed a single-arm phase II multicenter trial of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone (R-GCV …
Haptoglobin in Juvenile Idiopathic Arthritis.
Berntson L, Palm J, Axling F, Zarelius P, Hellström PM, Webb DL. Berntson L, et al. Among authors: webb dl. Pediatr Rheumatol Online J. 2022 Dec 15;20(1):117. doi: 10.1186/s12969-022-00777-5. Pediatr Rheumatol Online J. 2022. PMID: 36517828 Free PMC article.

Hp concentrations correlated with JADAS27, albumin (negatively), CRP and SAA with immunoturbidimetric method correlating strongest to JADAS27 (Spearman R ~ 0.6, p < 0.0001). CONCLUSION: Hp allele frequency in JIA is similar to the general population, indicating that chi

…
Hp concentrations correlated with JADAS27, albumin (negatively), CRP and SAA with immunoturbidimetric method correlating strongest to JADAS2 …
Acoustic properties across the human skull.
Riis TS, Webb TD, Kubanek J. Riis TS, et al. Among authors: webb td. Ultrasonics. 2022 Feb;119:106591. doi: 10.1016/j.ultras.2021.106591. Epub 2021 Oct 21. Ultrasonics. 2022. PMID: 34717144 Free PMC article.
In addition, we found that across skull regions, transmission strongly anti-correlated (R=-0.79) and phase distortion correlated (R=0.85) with skull thickness. ...
In addition, we found that across skull regions, transmission strongly anti-correlated (R=-0.79) and phase distortion correlated ( …
Adipocyte-Derived Serum Amyloid A Promotes Angiotensin II-Induced Abdominal Aortic Aneurysms in Obese C57BL/6J Mice.
Shridas P, Ji A, Trumbauer AC, Noffsinger VP, Leung SW, Dugan AJ, Thatcher SE, Cassis LA, de Beer FC, Webb NR, Tannock LR. Shridas P, et al. Among authors: webb nr. Arterioscler Thromb Vasc Biol. 2022 May;42(5):632-643. doi: 10.1161/ATVBAHA.121.317225. Epub 2022 Mar 28. Arterioscler Thromb Vasc Biol. 2022. PMID: 35344382 Free PMC article.
Surface topographical factors influencing bacterial attachment.
Crawford RJ, Webb HK, Truong VK, Hasan J, Ivanova EP. Crawford RJ, et al. Among authors: webb hk. Adv Colloid Interface Sci. 2012 Nov 1;179-182:142-9. doi: 10.1016/j.cis.2012.06.015. Epub 2012 Jul 4. Adv Colloid Interface Sci. 2012. PMID: 22841530 Review.
The most commonly reported surface roughness parameters are average and root mean square (RMS) roughness (R(a) and R(q) respectively), which are both measures of the typical height variation of the surface. ...
The most commonly reported surface roughness parameters are average and root mean square (RMS) roughness (R(a) and R(q) respec …
Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves.
Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG, Treede H, Sarano ME, Feldman T, Wijeysundera HC, Topilsky Y, Aupart M, Reardon MJ, Mackensen GB, Szeto WY, Kornowski R, Gammie JS, Yoganathan AP, Arbel Y, Borger MA, Simonato M, Reisman M, Makkar RR, Abizaid A, McCabe JM, Dahle G, Aldea GS, Leipsic J, Pibarot P, Moat NE, Mack MJ, Kappetein AP, Leon MB; VIVID (Valve in Valve International Data) Investigators. Dvir D, et al. Among authors: webb jg. Circulation. 2018 Jan 23;137(4):388-399. doi: 10.1161/CIRCULATIONAHA.117.030729. Circulation. 2018. PMID: 29358344 Review.
1,212 results